Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2026.Jul.06

News

OBI Pharma’s Obrion® ADC Technology Platform Wins Product Innovation of the Year at the 2026 Taiwan BIO Awards

2026.Jun.26

News

OBI Holds 2026 Annual Shareholders’ Meeting
Capturing Global Opportunities in Next-Generation ADCs with Its Proprietary Obrion® Platform to Advance Bispecific Dual-Payload ADCs and International Licensing Strategy

2026.Jun.11

News

OBI Presents Three Featured Talks at the 2026 World ADC Summit South Korea
Highlighting GlycOBI® and Dual-Payload ADC Technologies

Read More

2026.Sep.10

Announcement

The Company’s BOD approved to in-license antibody sequences from an U.S. university to strengthen OBI’s next-generation ADC pipeline

2026.Sep.10

Announcement

The Company’s Board of Directors resolved to revise 2026 Employee Stock Option Issuance and Subscription Rules

2026.Aug.21

Announcement

Announcement of Changes in the Company’s Internal Audit Officer

2025 Annual Report

Learn how we created value in 2025 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Driving Value Transformation Through ADC Innovation

Download PDF

Read More

2026 Annual Shareholders’ Meeting

  • 2026.Jun.26 at 09:00 AM
  • Taipei Bioinnovation Park 1F Conference Room
Youtube

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact